TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  News From NINDS  »  Proceedings  » 

Skip secondary menu

NIH Symposium on Progranulin and the TDP-43 Proteinopathies

Washington, D.C.
February 4-5, 2008

Frontotemporal lobar degeneration (FTLD) is the second most common cause of early-onset dementia after Alzheimer disease (AD).1  The estimated prevalence is 9 to 15 per 100,000 for those 45 to 64 years of age.2, 3  Symptoms typically appear in midlife, and include changes in personality and social conduct, including inertia, loss of volition and disinhibition.  These changes are followed by more global cognitive decline and eventual dementia.  In some cases, FTLD is accompanied by signs of Parkinson disease or motor neuron disease (MND) or both. Pathologic investigations have revealed at least three different forms of FTLD: FTLD with tau-positive inclusions (FTLD-tau), FTLD with tau-negative, ubiquitin-positive inclusions (FTLD-U), and FTLD without inclusions.4

A positive family history is observed in up to 50% of all FTLD patients, indicating a strong genetic component to these disorders.3  The first disease-causing mutations were identified in 1998, in the microtubule-associated protein tau gene (MAPT) on chromosome 17q21.5  These mutations were associated with FTLD-tau pathology, but not FTLD-U pathology.  In 2006 mutations associated with FTLD-U were identified as a second gene on 17q21, the gene for progranulin (GRN).6, 7  At about the same time, the major protein component of the ubiquitin-positive inclusions in FTLD-U was identified as trans-active response DNA-binding protein of 43-kDa molecular weight (TDP-43).8  More recently, a small subset of cases of FTLD-U have been reported that fail to show TDP-43 immunoreactivity, 9-11 suggesting additional heterogeneity in FTLD-U that requires further investigation.  Moreover, it has been suggested that terminology be developed to differentiate FTLD-U cases with TDP-43 immunoreactivity (e.g., FTLD-TDP) from those that are negative for TDP-43.

Progress has occurred rapidly in the two years since these discoveries were made.  In February 2008, NINDS held a workshop to assess the current state of the field and determine future priorities for research on progranulin, TDP-43 and FTLD-U.  The results of that workshop are reported here.

Mutations in the gene for progranulin (GRN) in FTLD-U


Mutations in GRN are a significant contributor to the total burden of FTLD, accounting for at least as many as mutations in MAPT.12  Current data indicate that GRN mutations are responsible for 5-10% of all cases of FTLD, 13-25% of familial cases, and 25% of cases with the FTLD-U pathologic subtype.12

At least 62 different pathogenic GRN mutations have been discovered so far worldwide.  All of them create functional null alleles, causing reduced progranulin expression and haploinsufficiency.  The mutations are found scattered throughout the gene and are of various types, including insertions, deletions and splice site mutations.  Most of the mutations introduce a premature termination codon and lead to degradation of mutant mRNA.  Genotype-phenotype analyses to date have shown no correlation between the type or location of GRN mutation and age of disease onset, clinical symptoms or neuropathology.13-15  Since age of onset and clinical presentation are highly variable, other genetic or environmental factors must interact with GRN mutations to influence phenotype.  Missense mutations have also been identified, but the significance of these mutations is not yet clear.16, 17  A current database of mutations associated with FTD can be found at:

Clinical phenotypes

Behavioral variant of FTD (FTDbv) is the most common clinical phenotype associated with GRN mutations.  In a recent genotype-phenotype study, for example, FTDbv was seen in 63% of cases at the time of inclusion in the study.13  Language disorders are the next most common presenting phenotype, with progressive non-fluent aphasia (PNFA) being the most prominent of these.  PNFA is the primary clinical diagnosis in 9 to 36% of patients with GRN mutations.  Patients may also exhibit extrapyramidal signs, including features of parkinsonism or corticobasal syndrome.

Visual hallucinations are also seen in a relatively high proportion (30%) of GRN mutation carriers, and it has been suggested that this symptom might help distinguish patients with GRN mutations from other FTD patients.18  In contrast to FTLD patients with MAPT mutations, those with GRN mutations rarely have motor neuron degeneration (MND).13  Patients with GRN mutations also differ from those with MAPT mutations in the nature of their language disorders, which includes PNFA, but not semantic dementia (SD).19  Age of disease onset is also earlier in GRN than in MAPT mutation carriers, but is still highly variable and cannot be used as a predictor of genotype.13  In some series disease duration is shorter in patients with GRN mutations, but this is not found in all series.20

Neuropathologic phenotypes

Mutations in GRN produce a relatively consistent pattern of neuropathology.14, 15, 21  It is characterized by cerebral atrophy that is most severe in frontal and temporal lobes, but in some cases may also affect parietal lobes.  In many cases atrophy is also seen in the caudate nucleus, and some cases have pathologic changes in the substantia nigra.  All of the aforementioned brain regions show neuronal loss, astrocytic gliosis and microglial activation.  The hippocampus is also affected, with loss of pyramidal cells in a pattern consistent with hippocampal sclerosis.15

The neuropathological signature of FTLD-U is a characteristic pattern of inclusions that show ubiquitin and TDP-43 immunoreactivity, in the form of neurites, neuronal cytoplasmic inclusions (NCI) and neuronal intranuclear inclusions (NII).  In GRN mutation carriers, these changes are particularly severe in upper layers of the cortex and in the neostriatum.  All cases reported to date have had NII and most NII have a characteristic lentiform shape.14  NII are not specific to GRN-related FTLD-U, since they can be detected in cases with no family history of FTLD.15 and they are numerous in patients with valosin containing protein (VCP) mutations.22  There is a range of morphologies of NCI in FTLD-U using both ubiquitin and TDP-43 immunohistochemistry, including NCI with crescent or ring-shapes, dense round shapes and those with a diffuse granular cytoplasmic immunoreactivity.  NCI are common in cortex, hippocampal dentate fascia and neostriatum.

While some cases of FTLD have neurodegeneration and neuronal loss in upper or lower motor neurons or both (FTLD-MND),23 most cases of FTLD-U associated with GRN mutations do not.  Thus, FTLD-U due to GRN mutations can usually be distinguished from other forms of FTLD by the combination of (1) severe pathology in the superficial neocortex and the striatum, (2) the presence of lentiform NII in these structures, (3) granular NCI in the hippocampus, and (4) absence of lower motor neuron involvement.  On the other hand, it should be cautioned that this pattern can also be detected in cases with no family history of FTLD.


Progranulin distribution and function

Progranulin is a 593 amino acid, cysteine-rich protein that was originally identified as the precursor of smaller related peptides referred to as granulins that were isolated from inflammatory exudates and later shown to be a product of activated leukocytes.24  Progranulin contains six and one half conserved granulin-like domains, each consisting of tandem repeats of a 12-cysteinyl motif.25  Extracellular proteases such as elastase can cleave progranulin to generate smaller peptides, called granulins or epithelins.26

In non-neural tissues

Progranulin is expressed in a variety of peripheral tissues as well as in the nervous system.  It is particularly prominent in epithelial and hematopoietic cells, and tends to be more highly expressed in tissues with high turnover rates (e.g., gastric mucosa, lymphoid tissue, tumor cell lines).27, 28 Progranulin is mitogenic for epithelial cells and several kinds of cancer cells, and it also promotes tumor cell invasiveness. 29-34  Progranulin is upregulated during wound healing, and it stimulates neutrophil and macrophage infiltration and neovascularization of wound tissue.26, 35

Progranulin and granulins also regulate inflammation, through opposing effects  The balance of progranulin and granulin effects is in turn regulated by elastase and other proteases, which cleave progranulin to form granulins and secretory leukocyte protease inhibitor (SLPI).35  SLPI is a 14-kDa protein secreted by neutrophils and macrophages, which inhibits the generation of granulins by both binding to progranulin cleavage sites and by direct inhibition of elastase.  Hence, SLPI acts to suppress inflammation and normalize wound healing, and is pro-tumorigenic. 

In the nervous system

Progranulin is expressed in a number of different neuronal populations in the adult central nervous system, including cortical and hippocampal pyramidal cells.36  Its distribution does not coincide with the pathology of FTLD-U, and it is not associated with NCI or neurites.  It is expressed in the cerebellum and brainstem, neither of which shows significant pathology in FTLD-U.  At the cellular level, progranulin immunoreactivity is found in neuronal perikarya, dendrites and axons.  It is expressed in a punctate, vesicular pattern similar to that seen with mitochondrial or endosomal-lysosomal markers; however, the precise subcellular localization of progranulin in neurons is still under investigation.

Many non-neuronal cell types also express progranulin.  It is especially prominent in microglia and macrophages,6 but is also present in endothelial and smooth muscle cells and in the choroid plexus and ependyma.  There is little or no progranulin immunoreactivity in oligodendrocytes or astrocytes under normal conditions, but it is expressed in reactive astrocytes, which are thought to be the major cell type that expresses SLPI in the brain.

The function of progranulin in the normal nervous system is just starting to be explored.  The one study to date characterizing GRN knockout mice focused on behavioral phenotypes in males and reported increased levels of aggression and anxiety.37  Effects of deficiency of progranulin in aging mice have not yet been reported.  In vitro studies indicate that progranulin may have neurotrophic effects.  It enhances cortical and motor neuron survival, and enhances neurite length.38  This effect is blocked by SLPI, suggesting it requires processing of progranulin to granulin.  Consistent with a role in neurodevelopment, progranulin is expressed in the neuroepithelium during the early proliferative phase, and continues to be expressed at high levels in the forebrain during formation of the cortex.27  Given increasing evidence that some neurodegenerative disease processes start early in life, additional studies of the functions of progranulin in the developing nervous system seem warranted.

Progranulin and nervous system disease

Progranulin mRNA levels are increased in a number of neurodegenerative disorders in which microglial activation occurs, including lysosomal storage disorders, viral encephalitis, prion related disorders and amyotrophic lateral sclerosis (ALS).36  In Alzheimer disease (AD), both microglia and dystrophic neurites in senile plaques have high levels of progranulin immunoreactivity, which is associated with autophagic structures at the ultrastructural level.  Progranulin is upregulated in response to hypoxia and acidotic stress in fibroblasts in culture.39  The responses of neural and glial progranulin levels to physiological stressors has not yet been reported; however, it has been shown that astrocytic SLPI is upregulated in ischemic stroke, and that SLPI has neuroprotective effects in a rodent model of stroke.40

The pathogenic molecular events occurring downstream of GRN mutations in FTLD-U remain to be determined.  The intracellular accumulation of pathological forms of TDP-43 is a consistent feature of most FTLD-U cases with and without GRN mutations, and it may represent a common final pathway leading to neurodegeneration.  Recent microarray analyses of the brains of FTLD‑U patients attempted to identify other molecular contributors to the disease process. 41, 42  Among the altered genes were those that are altered in a number of other neurodegeneratives diseases as well (axon guidance, focal adhesion, and regulation of actin cytoskeleton) and two categories that are so far unique to FTLD-U (TGF-beta signaling and cell cycle).  The unique gene pathways are of particular interest because they are involved in wound healing, a process known to be regulated by progranulin in the periphery.

TDP-43 and the FTD/ALS Connection

Ubiquitin-positive NCI are a pathological hallmark of both FTLD-U and ALS.  The major protein component of these inclusions is TDP-43,8 a 414-amino acid nuclear protein encoded by the gene TAR DNA-binding protein (TARDBP) on chromosome 1p36.2.43  TDP-43 is ubiquitously expressed, and is involved in the regulation of gene expression and splicing.44, 45  Mutations of TARDBP segregating with disease have now been identified in a small number of ALS families.46, 47

In FTLD-U, TDP-43 undergoes pathological modifications, including phosphorylation, ubiquitination and cleavage to generate C-terminal fragments, and is redistributed from the nucleus to the cytoplasm.  Cell culture studies have shown that decreased expression of progranulin with small inhibitory RNA can stimulate cleavage of TDP-43 by caspase 3, causing aberrant TDP-43 processing and distribution similar to that seen in diseased tissue.48  Mutagenesis of putative TDP-43 nuclear targeting sequences also recapitulates the pathological redistribution of the protein to the cytoplasm, and the formation of insoluble aggregates.49

The TDP-43 inclusions in ALS have a similar biochemical profile as those in FTLD-U, suggesting common pathogenic mechanisms of the two disorders.50  Consistent with this idea, a GRN variant has been identified in ALS patients and appears to affect disease progression.  FTLD and ALS share common phenotypes as well.  Up to 50% of ALS patients have behavioral changes and disturbances of executive function,51 and a subpopulation of FTLD patients have electrodiagnostic or pathologic evidence of motor neuron disease 52 (although, again motor neuron disease is not a typical feature of FTLD-U due to GRN mutations).  In some families FTD and ALS are also present and segregate with linkage on chromosome 9.53-55

Abnormal TDP-43-positive NCI and NII are characteristic of FTD associated with inclusion body myositis and Paget’s disease of the bone (IBMPFD), a rare multi-system disorder that includes muscle weakness, bone disease, and (in many cases) early-onset FTD.22, 56, 57  IBMPFD is caused by mutations in VCP on chromosome 9.58, 59  Thus, a key challenge for the future will be to identify common and unique pathogenic pathways in FTLD-U, ALS and IBMPFD.


1.    Genetic basis of FTD

GRN mutations
  • Determine epidemiological studies of GRN frequency in different geographic and ethnic populations.
  • Continue to determine the range of different types of mutations that are pathogenic.
  • Determine whether GRN mutations are pathogenic for other neurodegenerative conditions beyond FTD.
  • Determine whether GRN polymorphisms increase the risk of FTD or other neurodegenerative conditions.
  • Determine the genetic and environmental factors that influence age of disease onset and phenotypic expression of GRN mutations.
  • Identify other genes that could affect progranulin expression (i.e. SLPI).
Non-GRN gene mutations
  • Identify the gene on chromosome 9 responsible for FTLD-MND.
  • Identify genetic risk factors for sporadic FTLD-U.
  • Identify additional genes for FTLD-U that can explain the remaining FTLD-U families.

 2.    Progranulin function in normal brain

  • Confirm the role of progranulin as neuronal survival factor.
  • Define the fate and metabolism of progranulin in neuronal systems.
  • Define the secretory mechanism.
  • Identify receptor(s) for progranulin.
  • Determine normal intracellular localization.
  • Develop animal and in vitro models for progranulin function and regulation in neurons and microglia.
  • Understand why progranulin is high in neurons all the time instead of just after injury as in most other cells.
  • Determine normal levels of progranulin in brain and other tissues and biological fluids and determine factors that influence levels such as diurnal cycle, age, sex, other diseases, drugs.
  • Develop a bioassay for progranulin levels in brain.
  • Determine the toxicity, biological effects, and best delivery methods of exogenously administered progranulin, its derivatives, and related molecules in animals.

3.    Progranulin disease mechanisms

  • Determine if the disease is caused by deficiency of progranulin in neurons or microglia.
  • Assess microglial function and inflammatory responses in FTLD-U with and without GRN mutations.
  • Determine if there is a decreased incidence of cancer or increased incidence of autoimmune disease in individuals with GRN mutations.
  • Determine if progranulin has a role in primary CNS tumors.
  • Understand anatomical selective vulnerability associated with progranulin deficiency produced by GRN mutations.
  • Develop cell and animal models for progranulin.
  • Develop a bioassay.
  • Test compounds that influence progranulin expression.

4.    Natural history of FTD

  • Study preclinical familial FTD (i.e., with PGRN or VCP mutations) to determine earliest stages of disease.

5.    Role of TDP-43 in neurodegeneration

  • Determine normal functions of TDP-43 in neurons.
  • Understand basic mechanisms of TDP-43 accumulation (loss of function or toxic gain of function mechanism?)
  • Identify mutations and polymorphic variations in TARDBP that are pathogenic or affect risk of neurodegenerative disease (especially, FTLD and ALS).
  • Define the biochemical signature of pathological forms of TDP-43 (size of C-terminal fragments, phosphorylation state, folding conformation, aggregation state) and look for correlations with patterns of neuropathology and clinical phenotype.
  • Develop antibodies against phosphorylated sites, C-terminal and N-terminal of TDP-43.
  • Clarify role of TDP-43 in other neurodegenerative conditions (i.e. AD, DLB, tauopathies including Guam parkinsonism-dementia complex).
  • Develop animal and in vitro models to study TDP-43 function and effects of overexpression, mis-processing.
  • Determine relationship between FTD gene abnormalities (GRN, VCP, chrom 9p) and TDP-43 metabolism (e.g. through use of model systems including cell culture, flies, worms, zebrafish, and mouse).
  • Develop bioassay of levels of pathological TDP-43 in biological fluids (e.g., CSF).
  • Develop biomarkers for TDP-43 in vivo (i.e. neuro-imaging ligands).
  • Elucidate aggregation, disaggregation and elimination mechanisms of TDP-43.

6.    Administrative recommendations

  • Establish a mechanism for future funding to recruit and follow families with GRN, VCP and MAPT (and other relevant) mutations through a cross-institutional consortium that would unlikely to be amenable by current R01 funding mechanisms.
    • Current individual centers have only modest statistical power and there is considerable expense involved in such long-term family-based studies.\
    •  A multi-institutional consortium with a common research protocol would facilitate studies, optimize resources and provide a means to test new disease modifying therapies.


  1. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554
  2. Ratnavalli E, Brayne C, Dawson K, Hodges JR: The prevalence of frontotemporal dementia. Neurology 2002, 58:1615-1621
  3. Rosso SM, Donker Kaat L, Baks T, Joosse M, de Koning I, Pijnenburg Y, de Jong D, Dooijes D, Kamphorst W, Ravid R, Niermeijer MF, Verheij F, Kremer HP, Scheltens P, van Duijn CM, Heutink P, van Swieten JC: Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003, 126:2016-2022
  4. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, Chatterjee A, Hurtig HI, Karlawish JH, Rosen HJ, Van Deerlin V, Lee VM, Miller BL, Trojanowski JQ, Grossman M: Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006, 59:952-962
  5. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P: Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705
  6. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, 442:916-919
  7. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van Broeckhoven C: Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006, 442:920-924
  8. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschman HA, Trojanowski JQ, Lee VM-Y: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133
  9. Mackenzie IR, Foti D, Woulfe J, Hurwitz TA: Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 2008, 131:1282-1293
  10. Hatanpaa KJ, Bigio EH, Cairns NJ, Womack KB, Weintraub S, Morris JC, Foong C, Xiao G, Hladik C, Mantanona TY, White CL, 3rd: TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J Neuropathol Exp Neurol 2008, 67:271-279
  11. Pikkarainen M, Hartikainen P, Alafuzoff I: Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. J Neuropathol Exp Neurol 2008, 67:280-298
  12. Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S, Kuntz K, Petersen R, Josephs K, Pickering-Brown SM, Graff-Radford N, Uitti R, Dickson D, Wszolek Z, Gonzalez J, Beach TG, Bigio E, Johnson N, Weintraub S, Mesulam M, White CL, 3rd, Woodruff B, Caselli R, Hsiung GY, Feldman H, Knopman D, Hutton M, Rademakers R: Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006, 15:2988-3001
  13. Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, Spina S, Coppola G, Karydas AM, Stewart H, Johnson N, Hsiung GY, Kelley B, Kuntz K, Steinbart E, Wood EM, Yu CE, Josephs K, Sorenson E, Womack KB, Weintraub S, Pickering-Brown SM, Schofield PR, Brooks WS, Van Deerlin VM, Snowden J, Clark CM, Kertesz A, Boylan K, Ghetti B, Neary D, Schellenberg GD, Beach TG, Mesulam M, Mann D, Grafman J, Mackenzie IR, Feldman H, Bird T, Petersen R, Knopman D, Boeve B, Geschwind DH, Miller B, Wszolek Z, Lippa C, Bigio EH, Dickson D, Graff-Radford N, Hutton M: Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol 2007, 6:857-868
  14. Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E, Gass J, Cannon A, Rademakers R, Hutton M, Feldman HH: The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 2006, 129:3081-3090
  15. Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF, Knopman DS, Petersen RC, Davies P, Duara R, Graff-Radford NR, Uitti RJ, Rademakers R, Adamson J, Baker M, Hutton ML, Dickson DW: Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol 2007, 66:142-151
  16. Shankaran SS, Capell A, Hruscha AT, Fellerer K, Neumann M, Schmid B, Haass C: Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J Biol Chem 2008, 283:1744-1753
  17. van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijselinck I, Camuzat A, Brouwers N, Vandenberghe R, Sleegers K, Hannequin D, Dermaut B, Schymkowitz J, Campion D, Santens P, Martin JJ, Lacomblez L, De Pooter T, Peeters K, Mattheijssens M, Vercelletto M, Van den Broeck M, Cruts M, De Deyn PP, Rousseau F, Brice A, Van Broeckhoven C: Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat 2007, 28:416
  18. Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, Puel M, Laquerriere A, De Pooter T, Camuzat A, Van den Broeck M, Dubois B, Sellal F, Lacomblez L, Vercelletto M, Thomas-Anterion C, Michel BF, Golfier V, Didic M, Salachas F, Duyckaerts C, Cruts M, Verpillat P, Van Broeckhoven C, Brice A: Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 2007, 28:846-855
  19. Snowden JS, Pickering-Brown SM, Mackenzie IR, Richardson AM, Varma A, Neary D, Mann DM: Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain 2006, 129:3091-3102
  20. Pickering-Brown SM, Rollinson S, Du Plessis D, Morrison KE, Varma A, Richardson AM, Neary D, Snowden JS, Mann DM: Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain 2008, 131:721-731
  21. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL, 3rd, Schneider JA, Kretzschmar HA, Carter D, Taylor-Reinwald L, Paulsmeyer K, Strider J, Gitcho M, Goate AM, Morris JC, Mishra M, Kwong LK, Stieber A, Xu Y, Forman MS, Trojanowski JQ, Lee VM, Mackenzie IR: TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin Inclusions. Am J Pathol 2007, 171:227-240
  22. Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, Jhaveri BS, Karlawish JH, Pestronk A, Smith TW, Tu PH, Watts GD, Markesbery WR, Smith CD, Kimonis VE: Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 2006, 65:571-581
  23. Katsuse O, Dickson DW: Ubiquitin immunohistochemistry of frontotemporal lobar degeneration differentiates cases with and without motor neuron disease. Alzheimer Dis Assoc Disord 2005, 19 Suppl 1:S37-43
  24. Bateman A, Belcourt D, Bennett H, Lazure C, Solomon S: Granulins, a novel class of peptide from leukocytes. Biochem Biophys Res Commun 1990, 173:1161-1168
  25. Bhandari V, Palfree RG, Bateman A: Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proc Natl Acad Sci USA 1992, 89:1715-1719
  26. Zanocco-Marani T, Bateman A, Romano G, Valentinis B, He ZH, Baserga R: Biological activities and signaling pathways of the granulin/epithelin precursor. Cancer Res 1999, 59:5331-5340
  27. Daniel R, Daniels E, He Z, Bateman A: Progranulin (acrogranin/PC cell-derived growth factor/granulin-epithelin precursor) is expressed in the placenta, epidermis, microvasculature, and brain during murine development. Dev Dyn 2003, 227:593-599
  28. Serrero G, Ioffe OB: Expression of PC-cell-derived growth factor in benign and malignant human breast epithelium. Hum Pathol 2003, 34:1148-1154
  29. Davidson B, Alejandro E, Florenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC: Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer 2004, 100:2139-2147
  30. He Z, Ismail A, Kriazhev L, Sadvakassova G, Bateman A: Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res 2002, 62:5590-5596
  31. Monami G, Gonzalez EM, Hellman M, Gomella LG, Baffa R, Iozzo RV, Morrione A: Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res 2006, 66:7103-7110
  32. Tangkeangsirisin W, Serrero G: PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis 2004, 25:1587-1592
  33. Matsumura N, Mandai M, Miyanishi M, Fukuhara K, Baba T, Higuchi T, Kariya M, Takakura K, Fujii S: Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in vivo tumorigenesis. Clin Cancer Res 2006, 12:1402-1411
  34. Zhou J, Gao G, Crabb JW, Serrero G: Purification of an autocrine growth factor homologous with mouse epithelin precursor from a highly tumorigenic cell line. J Biol Chem 1993, 268:10863-10869
  35. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, Ding A: Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002, 111:867-878
  36. Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW: Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007, 4:7
  37. Kayasuga Y, Chiba S, Suzuki M, Kikusui T, Matsuwaki T, Yamanouchi K, Kotaki H, Horai R, Iwakura Y, Nishihara M: Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav Brain Res 2007, 185:110-118
  38. Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, van Swieten J, Carmeliet P, Van Den Bosch L, Robberecht W: Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 2008, 181:37-41
  39. Guerra RR, Kriazhev L, Hernandez-Blazquez FJ, Bateman A: Progranulin is a stress-response factor in fibroblasts subjected to hypoxia and acidosis. Growth Factors 2007, 25:280-285
  40. Ilzecka J, Stelmasiak Z: Increased serum levels of endogenous protectant secretory leukocyte protease inhibitor in acute ischemic stroke patients. Cerebrovasc Dis 2002, 13:38-42
  41. Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong LK, Yuan W, Grossman M, Van Deerlin VM, Trojanowski JQ, Lee VM: Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum Mol Genet 2008, 17:1349-1362
  42. Mishra M, Paunesku T, Woloschak GE, Siddique T, Zhu LJ, Lin S, Greco K, Bigio EH: Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol 2007, 114:81-94
  43. Wang HY, Wang IF, Bose J, Shen CK: Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 2004, 83:130-139
  44. Buratti E, Baralle FE: Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 2001, 276:36337-36343
  45. Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE: Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 2001, 20:1774-1784
  46. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF, Camu W, Meininger V, Dupre N, Rouleau GA: TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008, 40:572-574
  47. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE: TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672
  48. Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, Pickering-Brown S, Dickson D, Petrucelli L: Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 2007, 27:10530-10534
  49. Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM: Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem 2008, 283:13302-13309
  50. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133
  51. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B: Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003, 60:1094-1097
  52. Josephs KA, Parisi JE, Knopman DS, Boeve BF, Petersen RC, Dickson DW: Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol 2006, 63:506-512
  53. Hosler BA, Siddique T, Sapp PC, Sailor W, Huang MC, Hossain A, Daube JR, Nance M, Fan C, Kaplan J, Hung WY, McKenna-Yasek D, Haines JL, Pericak-Vance MA, Horvitz HR, Brown RH, Jr.: Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000, 284:1664-1669
  54. Morita M, Al-Chalabi A, Andersen PM, Hosler B, Sapp P, Englund E, Mitchell JE, Habgood JJ, de Belleroche J, Xi J, Jongjaroenprasert W, Horvitz HR, Gunnarsson LG, Brown RH, Jr.: A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006, 66:839-844
  55. Valdmanis PN, Dupre N, Bouchard JP, Camu W, Salachas F, Meininger V, Strong M, Rouleau GA: Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. Arch Neurol 2007, 64:240-245
  56. Kimonis VE, Watts GD: Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis Assoc Disord 2005, 19 Suppl 1:S44-47
  57. Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, Taylor JP, Kretzschmar HA, Kimonis VE, Forman MS: TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 2007, 66:152-157
  58. Haubenberger D, Bittner RE, Rauch-Shorny S, Zimprich F, Mannhalter C, Wagner L, Mineva I, Vass K, Auff E, Zimprich A: Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology 2005, 65:1304-1305
  59. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE: Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004, 36:377-381

Participant List

Irina Alafuzoff, M.D., Ph.D., University of Kuopio, Kuopio, Finland

Andrew Bateman, Ph.D., McGill University, Montreal, Canada

Eileen Bigio, M.D., Northwestern University, Chicago, IL

Bradley Boeve, M.D., Mayo Clinic, Rochester, MN

Nigel Cairns, Ph.D., MRCPath, Washington University, St. Louis, MO

Alice Chen-Plotkin, M.D., University of Pennsylvania, Philadelphia, PA

Susan Dickinson, M.S., The Association for Frontotemporal Dementias, Philadelphia, PA

Dennis W. Dickson, M.D., Mayo Clinic, Jacksonville, FL

Diane DiEullis, Ph.D., NINDS/NIH, Bethesda, MD

Aihao Ding, Ph.D., Weill Medical College of Cornell University, New York, NY

Matthew Frosch, M.D., Ph.D., Massachusetts General Hospital, Boston, MA

Wendy Galpern, M.D., Ph.D., NINDS/NIH, Bethesda, MD

Felix Geser, M.D., Ph.D., University of Pennsylvania, Philadelphia, PA

Bernadino Ghetti, M.D>50, Indian Univeristy, Indianapolis, IN

Murray Grossman, M.D., University of Pennsylvania, Philadelphia, PA

Katrina Gwinn, M.D., NINDS/NIH, Bethesda, MD

Kimmo Hatanpaa, M.D., Ph.D. University of texas Southwestern, Dallas, TX

Lauren Herl, University of California, San Francisco, San Francisco, CA

Michael Hutton, Ph.D., Merck Research Laboratories, Boston, MA

Keith Josephs, M.S.T., M.D., Mayo Clinic, Rochester, MN

Aimee Kao,  M.D., Ph.D., University of California, San Francisco, San Francisco, CA

Virginia Kimonis, M.D., University of California, Irvine, Orange, CA

Elise Kohn, M.D., Center for Cancer Research, NCI/NIH, Bethesda, MD

Walter Koroshetz, M.D., NINDS/NIH, Bethesda, MD

Linda Kwong, Ph.D., University of Pennsylvania, Philadelphia, PA

Virginia M.-Y. Lee, Ph.D., University of Pennsylvania, Philadelphia, PA

Ti Lin, Ph.D., NINDS/NIH, Bethesda, MD

Philip Lovett, The Association for Frontotemporal Dementias, Philadelphia, PA

Ian Mackenzie, M.D., FRCPC, University of British Columbia, Vancouver, Canada

Maria Martinez-Lage, M.D., University of Pennsylvania, Philadelphia, PA

Bruce Miller, M.D., University of California, San Francisco, San Francisco, CA

Lionel Muller Igaz, Ph.D., University of Pennsylvania, Philadelphia, PA

Manuela Neumann, M.D., Ludwig-Maximilians University, Munich, Germany

Kiyomitsu Oyanagi, M.D. Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan

Catherine Pace-Savitsky, M.A., The Association for Frontotemporal Dementias, Philadelphia, PA

Scott Pesiridis, Ph.D., University of Pennsylvania, Philadelphia, PA

Leonard Petrucelli, Ph.D., Mayo Clinic, Jacksonville, FL

Creighton Phelps, NIA/NIH, Bethesda, MD

Stuart Pickering-Brown, Ph.D., University of Manchester, Manchester, England

Rosa Rademakers, Ph.D., Mayo Clinic, Jacksonville, FL

Tamas Revesz, M.D., University College London, London, England

Beth-Anne Sieber, Ph.D., NINDS/NIH, Bethesda, MD

Stephen Snyder, Ph.D., NIA/NIH, Bethesda, MD

Michael Strong, M.D., University of Western Ontario, London, Canada

Margaret Sutherland, Ph.D., NINDS/NIH, Bethesda, MD

John Trojanowski, M.D., Ph.D., University of Pennsylvania, Philadelphia, PA

Kunihiro Uryu, Ph.D., University of Pennsylvania, Philadelphia, PA

Christine Van Broeckhoven, PhD., D.Sc., University of Antwerp, Antwerp, Belgium

Vivianna Van Deerlin, M.D., Ph.D., University of Pennsylvania, Philadelphia, PA

J.C. van Swieten, M.D., Ph.D., Erasmus Medical center, Rotterdam, The Netherlands

Jean Paul Vonsattel, M.D., Columbia University, New York, NY

Matthew Winton, Ph.D., University of Pennsylvania, Philadelphia, PA

Jiping Xiao, Ph.D., University of Pennsylvania, Philadelphia, PA


Last Modified March 1, 2011